Loading...
•
Jun 30
Axogen Q2 2025 Earnings Report
Axogen reported strong financial results for the second quarter of 2025, with significant revenue growth and a return to net income.
Key Takeaways
Axogen, Inc. delivered a robust second quarter in 2025, achieving $56.7 million in revenue, an 18.3% increase year-over-year. The company reported a net income of $0.6 million, a significant improvement from a net loss in the prior year, and saw strong growth in adjusted EBITDA and gross margin.
Second quarter revenue reached $56.7 million, marking an 18.3% increase compared to the same period in 2024.
The company achieved a net income of $0.6 million ($0.01 per share), a positive shift from a net loss of $1.9 million in Q2 2024.
Adjusted EBITDA significantly increased to $9.3 million, up from $5.6 million in the second quarter of 2024.
Gross margin improved to 74.2% in Q2 2025, compared to 73.8% in Q2 2024.
Axogen
Axogen
Forward Guidance
Axogen has raised its full-year revenue guidance to at least 17% growth, or $219 million, and expects gross margin to be between 73% and 75%. The company also reiterates its expectation to be net cash flow positive for the full year.
Positive Outlook
- Raised full-year revenue guidance to at least 17% growth, targeting $219 million.
- Anticipated gross margin for the full year is expected to be in the range of 73% to 75%.
- Expectation to be net cash flow positive for the full year.
- FDA accepted the BLA filing for Avance® Nerve Graft with a PDUFA goal date of September 5, 2025.
- Completed key regulatory milestones for Avance® Nerve Graft approval, including late-cycle meeting, pre-licensing inspection, and sponsor inspection.
Challenges Ahead
- Gross margin for the year is expected to be negatively impacted by approximately 1% due to one-time costs related to the anticipated Avance® Nerve Graft BLA approval.
- No other specific negative forward guidance points were explicitly stated in the report beyond the gross margin impact.